Please login to the form below

Not currently logged in
Email:
Password:

Dr Antoine Yver moves from AstraZeneca to Daiichi Sankyo

He becomes global head, oncology research and development

Daiichi Sankyo Dr Antoine YverDaiichi Sankyo has appointed Dr Antoine Yver to the newly-created position of global head, oncology research and development.

Reporting directly to Dr Glenn Gormley, Daiichi Sankyo's president and global head of research and development, Dr Yver will oversee the entirety of the firm's global research and development in the oncology therapeutic area.

Dr Gormley said: “Antoine brings a strong track record of extensive scientific leadership in many facets of global oncology pharmaceutical research and development along with tremendous passion for science and patients.

“We are confident that Antoine will provide great leadership and strategic insights in this new role, which underscores Daiichi Sankyo's commitment to the fight against cancer.”

Dr Yver moves from AstraZeneca, where he has served as senior vice president and head of oncology global medicines development as well as leading its global medicines development in China since 2012.

Prior to this, he has held senior management roles in oncology research at Aventis, Johnson & Johnson and Schering-Plough.

Dr Yver said: “I'm excited to join such a respected company and further build its presence in this important field.

“I have been most impressed by the quality of science at Daiichi Sankyo and the company's strong commitment towards becoming an innovator in bringing new therapeutic options to people living with cancer.”

6th April 2016

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
JPA Health

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

Harness the power of data to map new patient pathways
Oli Hudson, of Wilmington Healthcare, explains why pharma needs to put data at the heart of its bid to support the NHS Reset...
What NORD’s RareInsights® 30-year comparative analysis means to us and our clients at OPEN Health
...
Peter Jackson
Rethinking our approach to infectious disease preparedness
The importance of long-term strategic investment to prepare for the next threat that emerges...

Infographics